TAIPEI, Taiwan, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mr. Steve Chen, Chairman of the Board of Directors of Success Entertainment Group International Inc. (OTCQB: SEGN) has stated that in recent years, healthcare related therapy and medication biotech to treat human anti-aging issues have evolved significantly. At the end of July, 2018, SEGN signed a Memorandum of Understanding with Taiwan EverLive Telomerase Limited whereby TETL will devote its research team to obtain more patent rights in addition to those already received from several countries. Both SEGN and TETL plan to embark on tours in Asia, particularly in China, to jointly promote Telomerase, utilizing Steve Chen’s huge fan club database that SEGN has accumulated over several years. The aim is to penetrate the vast worldwide population in need of such care.

About Success Entertainment Group International Inc.:
Success Entertainment Group International Inc. (OTCQB: SEGN), is an education + big database + video Sharing platform e-commerce based organization focusing on membership database platform buildup. Our company has been awarded operational IP rights by one of Asia’s prominent inspirational speakers, Steve Chen, through his fans global database. Over the years, Mr. Chen’s Company has accumulated enormous membership data streamlining through to e-commerce and video platforms in Asia, creating substantial revenue. Our strategies for the company is to acquire or partner with platforms alike, and apply the aforementioned fans databases, which spreads to the more than 100-million-person consumer population in Asia. Such revenue streams may contribute viable and steady growth to the Company.

IR Contact:
Success Entertainment Group International Inc.
www.segnusa.com
Email Contact: info@segnusa.com
Telephone: +1(260) 490-9990